Despite New Federal Actions, Prescription Drug Worry Hits Highest Level Since 2018

Why It Matters

Rising cost anxiety signals potential pressure on policymakers, employers, and insurers to intensify price‑control measures, while partisan perceptions could shape upcoming legislative battles over drug pricing reforms.

Key Takeaways

• 41% expect Trump policies lower drug costs
• Concern highest since 2018, 59% worried
• Low-income adults most anxious about prescriptions
• Two-thirds across parties want more regulation
• Democrats trusted more than Republicans for cost solutions

Pulse Analysis

The Biden‑era focus on drug pricing has shifted under the Trump administration, which relaunched the TrumpRx initiative to curb prescription costs. Yet KFF’s latest poll shows only 41 % of adults believe the new policies will lower their out‑of‑pocket expenses, with support clustering along party lines—nearly eight‑in‑ten Republicans remain optimistic, while just 11 % of Democrats share that view. This partisan divide underscores how political affiliation continues to shape perceptions of federal health‑care actions, even as the administration pushes regulatory reforms.

Public anxiety about medication affordability has surged to its highest level since 2018, with 59 % of respondents expressing worry. The sentiment is strongest among households earning under $40,000, where 67 % fear they cannot afford prescriptions, and among individuals taking four or more drugs, at 64 %. For employers and health‑plan sponsors, this heightened concern translates into pressure to enhance benefit designs, negotiate better pricing, and consider alternative therapies. The data signal that cost‑containment strategies must address both income disparities and polypharmacy trends to remain effective.

Looking ahead to the 2026 midterm elections, the Democratic Party enjoys a modest lead in voter trust for tackling drug prices—38 % versus 28 % for Republicans—while a quarter of voters remain disillusioned with both parties. This trust gap could fuel bipartisan legislative efforts or, conversely, entrench partisan stalemates that stall meaningful reform. Pharmaceutical manufacturers, insurers, and policymakers will be watching these dynamics closely, as any shift in regulatory posture could reshape pricing models, market competition, and ultimately, patient access to essential medicines.